RecruitingPhase 2NCT06902558
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Studying Autosomal dominant polycystic kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- ABBV-CLS-628(drug)
- Enrollment
- 240 enrolled
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2025 – 2029
Study locations (30)
- National Institute of Clinical Research - Garden Grove /ID# 271418, Garden Grove, California, United States
- Valiance Clinical Research - Huntington Park /ID# 270634, Huntington Park, California, United States
- Academic Medical Research Institute - Los Angeles /ID# 270502, Los Angeles, California, United States
- UC Irvine Medical Center /ID# 270811, Orange, California, United States
- University Of California, San Francisco /ID# 270326, San Francisco, California, United States
- Yale University School of Medicine /ID# 270675, New Haven, Connecticut, United States
- Horizon Research Group - Coral Gables /ID# 270857, Coral Gables, Florida, United States
- South Florida Research Institute /ID# 270848, Fort Lauderdale, Florida, United States
- Nature Coast Clinical Research - Inverness /ID# 270875, Inverness, Florida, United States
- Mayo Clinic Hospital Jacksonville /ID# 271011, Jacksonville, Florida, United States
- Panax Clinical Research /ID# 270851, Miami, Florida, United States
- Infigo Clinical Research /ID# 270844, Sanford, Florida, United States
- Emory University School Of Medicine - Atlanta /ID# 271947, Atlanta, Georgia, United States
- CARE-Boise Kidney /ID# 270628, Boise, Idaho, United States
- CARE Institute - Idaho Falls /ID# 272005, Idaho Falls, Idaho, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Calico Life Sciences LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06902558 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07454174Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseRichard Fatica
- RECRUITINGPHASE2NCT07161037Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07228364Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseaseAstraZeneca
- RECRUITINGNCT06970028Somatosensory Phenotyping of ADPKDUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGNCT07260071Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney DiseaseKing's College London
- ACTIVE NOT RECRUITINGNCT07016282Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational StudyMario Negri Institute for Pharmacological Research
- RECRUITINGPHASE1NCT06714006Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003PYC Therapeutics
- RECRUITINGPHASE2NCT06800651Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)Jemincare
See all trials for Autosomal dominant polycystic kidney disease →